Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Limit to evidence status or GRADE (optional)

1,554 questions in 140 reviews · Heart

current versions
No studies 272 · 17.5%Ungraded 44 · 2.8%Very low 329 · 21.2%Low 464 · 29.9%Moderate 319 · 20.5%High 126 · 8.1%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

QuestionEffectEvidenceStatus / GRADE
Exercise‐based cardiac rehabilitation vs usual care
All‐cause mortality · adults with heart failure
Exercise‐based cardiac rehabilitation for adults with heart failure (2024) · Cochrane
RR 0.93 [0.71, 1.21]34 studies · 3941 participantsLow
Exercise‐based cardiac rehabilitation vs usual care
All‐cause hospital admissions · adults with heart failure
Exercise‐based cardiac rehabilitation for adults with heart failure (2024) · Cochrane
RR 0.69 [0.56, 0.86]23 studies · 2283 participantsModerate
Exercise‐based cardiac rehabilitation vs usual care
HF‐related hospital admissions · adults with heart failure
Exercise‐based cardiac rehabilitation for adults with heart failure (2024) · Cochrane
RR 0.82 [0.49, 1.35]10 studies · 911 participantsModerate
Exercise‐based cardiac rehabilitation vs usual care
HRQoL (MLWHF only) · adults with heart failure
Exercise‐based cardiac rehabilitation for adults with heart failure (2024) · Cochrane
no estimate extracted21 studies · 2699 participantsModerate
Exercise‐based cardiac rehabilitation vs usual care
HRQoL (all measurement scales) · adults with heart failure
Exercise‐based cardiac rehabilitation for adults with heart failure (2024) · Cochrane
no estimate extracted33 studies · 4769 participantsVery low
Prophylactic corticosteroids vs placebo or no corticosteroids
All‐cause mortality (during the index hospital admission, or within 30 days, at the longest · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with…
Prophylactic corticosteroids for cardiopulmonary bypass in adult cardiac surgery (2024) · Cochrane
RR 0.9 [0.75, 1.07]25 studies · 14940 participantsLow
Prophylactic corticosteroids vs placebo or no corticosteroids
Cardiac complications (as defined by study authors, including cardiac compromise and fatal and non‐fatal myocardial infarction, defined as ECG changes, echocardiological changes, or disproportionate elevation of troponins, during the index hospita... · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with…
Prophylactic corticosteroids for cardiopulmonary bypass in adult cardiac surgery (2024) · Cochrane
RR 1.16 [1.04, 1.31]25 studies · 14766 participantsLow
Prophylactic corticosteroids vs placebo or no corticosteroids
Pulmonary complications (as defined by study authors, including pneumonia, embolism, reduced pulmonary function, prolonged ventilation, and pleural effusion, during the index hospital admission) · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with…
Prophylactic corticosteroids for cardiopulmonary bypass in adult cardiac surgery (2024) · Cochrane
RR 0.88 [0.78, 0.99]18 studies · 13549 participantsLow
Prophylactic corticosteroids vs placebo or no corticosteroids
Infectious complications (as defined by study authors, including mediastinitis, wound infections, pneumonia, and need for antibiotic therapy, during the index hospital admission) · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with…
Prophylactic corticosteroids for cardiopulmonary bypass in adult cardiac surgery (2024) · Cochrane
RR 0.84 [0.76, 0.92]28 studies · 14771 participantsLow
Prophylactic corticosteroids vs placebo or no corticosteroids
Gastrointestinal (GI) bleeding (as defined by study authors, including any upper and lower GI bleeding, during the index hospital admission) · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with…
Prophylactic corticosteroids for cardiopulmonary bypass in adult cardiac surgery (2024) · Cochrane
RR 1.21 [0.87, 1.67]6 studies · 12533 participantsLow
Prophylactic corticosteroids vs placebo or no corticosteroids
Renal failure (as defined by study authors, including dialysis, creatinine rise, and oliguria, during the index hospital admission) · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with…
Prophylactic corticosteroids for cardiopulmonary bypass in adult cardiac surgery (2024) · Cochrane
RR 0.84 [0.69, 1.02]13 studies · 12799 participantsLow
Prophylactic corticosteroids vs placebo or no corticosteroids
Length of hospital stay (measured in days, during the index hospital admission) · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with…
Prophylactic corticosteroids for cardiopulmonary bypass in adult cardiac surgery (2024) · Cochrane
no estimate extracted25 studies · 1841 participantsVery low
Mobile phone text messaging vs usual care
Medication adherence (self‐reported adherence, questionnaire, tablet counts, medication event monitoring systems, pharmacy prescription data) · people with established arterial occlusive events
Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted18 studies · 8136 participantsVery low
Mobile phone text messaging vs usual care
Fatal cardiovascular events (percentage of people having fatal cardiovascular events) · people with established arterial occlusive events
Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane
OR 0.83 [0.47, 1.45]4 studies · 1654 participantsLow
Mobile phone text messaging vs usual care
Non‐fatal cardiovascular events (percentage of people having non‐fatal cardiovascular events) · people with established arterial occlusive events
Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extractedNRVery low
Mobile phone text messaging vs usual care
Combined CVD events (percentage of people having combined CVD events) · people with established arterial occlusive events
Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extractedNRVery low
Mobile phone text messaging vs usual care
Low‐density lipoprotein cholesterol (mg/dL) (endpoint low‐density lipoprotein cholesterol reading) · people with established arterial occlusive events
Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted8 studies · 4983 participantsVery low
Mobile phone text messaging vs usual care
Blood pressure (mmHg) (endpoint blood pressure reading) · people with established arterial occlusive events
Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted8 studies · 5173 participantsVery low
Mobile phone text messaging vs usual care
Heart rate (beats per minute) (endpoint heart rate reading) · people with established arterial occlusive events
Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted4 studies · 2946 participantsVery low
Mindfulness‐based interventions (MBIs) vs active comparators
Clinical CVD events · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extractedNRNo studies
Mindfulness‐based interventions (MBIs) vs non‐active comparators
Clinical CVD events (CVD mortality and non‐fatal MI) · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
RR 0.94 [0.37, 2.42]1 study · 110 participantsVery low
Mindfulness‐based interventions (MBIs) vs non‐active comparators
Systolic blood pressure (mmHg), change from baseline · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted9 studies · 379 participantsLow
Mindfulness‐based interventions (MBIs) vs non‐active comparators
Diastolic blood pressure (mmHg), change from baseline · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted9 studies · 379 participantsLow
Mindfulness‐based interventions (MBIs) vs non‐active comparators
Anxiety, change from baseline · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted9 studies · 533 participantsLow
Mindfulness‐based interventions (MBIs) vs non‐active comparators
Depression, change from baseline · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted15 studies · 912 participantsLow
Mindfulness‐based interventions (MBIs) vs non‐active comparators
Perceived stress, change from baseline · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted11 studies · 708 participantsLow
Mindfulness‐based interventions (MBIs) vs non‐active comparators
Well‐being · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted2 studies · 198 participantsModerate
Mindfulness‐based interventions (MBIs) vs non‐active comparators
Adverse events · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
RR 5 [0.27, 91.52]1 study · 18 participantsLow
Mindfulness‐based interventions (MBIs) vs non‐active comparators
Smoking cessation · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
RR 1.36 [0.86, 2.13]2 studies · 453 participantsLow
Transcendental meditation (TM) vs active comparators
Clinical CVD events (CVD mortality, non‐fatal MI and stroke, revascularisations) · people at high risk of or with cardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
RR 0.91 [0.56, 1.49]1 study · 201 participantsLow
Mindfulness‐based interventions (MBIs) vs active comparators
Systolic blood pressure (mmHg), change from baseline · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted6 studies · 388 participantsLow
Transcendental meditation (TM) vs active comparators
Systolic blood pressure (mmHg), change from baseline · people at high risk of or with cardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted8 studies · 774 participantsModerate
Transcendental meditation (TM) vs active comparators
Diastolic blood pressure (mmHg), change from baseline · people at high risk of or with cardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted8 studies · 774 participantsLow
Transcendental meditation (TM) vs active comparators
Anxiety, change from baseline · people at high risk of or with cardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted3 studies · 200 participantsLow
Transcendental meditation (TM) vs active comparators
Depression, change from baseline · people at high risk of or with cardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted5 studies · 421 participantsModerate
Transcendental meditation (TM) vs active comparators
Perceived stress, change from baseline · people at high risk of or with cardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted3 studies · 194 participantsVery low
Transcendental meditation (TM) vs active comparators
Well‐being · people at high risk of or with cardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extractedNRNo studies
Transcendental meditation (TM) vs active comparators
Adverse events · people at high risk of or with cardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extractedNRNo studies
Transcendental meditation (TM) vs active comparators
Smoking cessation · people at high risk of or with cardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extractedNRNo studies
Transcendental meditation (TM) vs non‐active comparators
Clinical CVD events · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extractedNRNo studies
Transcendental meditation (TM) vs non‐active comparators
Systolic blood pressure (mmHg), change from baseline · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted2 studies · 139 participantsLow
Mindfulness‐based interventions (MBIs) vs active comparators
Diastolic blood pressure (mmHg), change from baseline · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted6 studies · 388 participantsLow
Transcendental meditation (TM) vs non‐active comparators
Diastolic blood pressure (mmHg), change from baseline · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted2 studies · 139 participantsLow
Transcendental meditation (TM) vs non‐active comparators
Anxiety, change from baseline · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted1 study · 112 participantsLow
Transcendental meditation (TM) vs non‐active comparators
Depression, change from baseline · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted1 study · 112 participantsLow
Transcendental meditation (TM) vs non‐active comparators
Perceived stress · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extractedNRNo studies
Transcendental meditation (TM) vs non‐active comparators
Well‐being · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extractedNRNo studies
Transcendental meditation (TM) vs non‐active comparators
Adverse events · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extractedNRNo studies
Transcendental meditation (TM) vs non‐active comparators
Smoking cessation · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extractedNRNo studies
Mindfulness‐based interventions (MBIs) vs active comparators
Anxiety, change from baseline · people at high risk of or withcardiovascular disease
Meditation for the primary and secondary prevention of cardiovascular disease (2024) · Cochrane
no estimate extracted9 studies · 438 participantsModerate